| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Jeffrey L. Ives is Director at TVRD and has filed Form 4s across 2 companies. Jeffrey L. Ives's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $177K at current prices.
Historically, Jeffrey L. Ives's trades have earned a middling insider score of 68/100 across 4 rated trades. Over a 12-month horizon, all 4 of those trades were profitable, with an average 12-month return of +48.7%.
The biggest single holding is TVRD (~$166K) as Director. The TVRD filings lean toward selling, a net 42,800 shares.
Jeffrey L. Ives has 32 Form 4 filings on record from June 2015 to June 2026, across 2 companies: Director at Acumen Pharmaceuticals (ABOS), 2021–2026; Director at Tvardi Therapeutics (TVRD), 2015–2024.
The 56 reported transactions were 17 open-market sales, 16 option or other derivative awards, 14 option exercises and 9 stock awards.
Counted by filing, the open-market trades come to no purchases and 16 sales worth about $1.0M.
The largest open-market sale was 41,949 shares of ABOS at an average $6.49 on August 17, 2023, about $272K. Twelve months later ABOS was down 60%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 17, 2023 | ABOS Acumen Pharmaceuticals, Inc. | Director | Sale+OE10b5-1 | 41,949 | $6.49 | $272,333.52 | - | -63.0% | -59.8% | |
| Jul 15, 2022 | TVRD Tvardi Therapeutics, Inc. | Director | Sell | 3,600 | $9.05 | $32,580.00 | -18.9% | +7.9% | -69.1% | |
| Nov 12, 2021 | TVRD Tvardi Therapeutics, Inc. | Director | Sell | 8,180 | $16.04 | $131,207.20 | -53.2% | -35.7% | -31.8% | |
| Jun 7, 2021 | TVRD Tvardi Therapeutics, Inc. | Director | Sell | 2,520 | $13.05 | $32,886.00 | -14.1% | +16.0% | -34.1% | |
| Jun 1, 2020 | TVRD Tvardi Therapeutics, Inc. | Director | Sale+OE | 1,000 | $16.00 | $16,000.00 | -14.3% | - | - | |
| May 12, 2020 | TVRD Tvardi Therapeutics, Inc. | Director | Sale+OE | 2,500 | $16.00 | $40,000.00 | -29.4% | - | - | |
| Apr 21, 2020 | TVRD Tvardi Therapeutics, Inc. | Director | Sale+OE | 2,500 | $16.00 | $40,000.00 | -29.4% | - | - | |
| Mar 4, 2020 | TVRD Tvardi Therapeutics, Inc. | Director | Sale+OE | 2,500 | $16.00 | $40,000.00 | -29.4% | - | - | |
| Feb 3, 2020 | TVRD Tvardi Therapeutics, Inc. | Director | Sale+OE | 2,500 | $16.23 | $40,575.00 | -29.4% | - | - | |
| Jan 2, 2020 | TVRD Tvardi Therapeutics, Inc. | Director | Sale+OE | 2,500 | $16.13 | $40,325.00 | -29.4% | - | - |